Compare IONS & SIMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IONS | SIMO |
|---|---|---|
| Founded | 1989 | 1995 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.4B |
| IPO Year | 1996 | 2005 |
| Metric | IONS | SIMO |
|---|---|---|
| Price | $54.24 | $262.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 9 |
| Target Price | $93.36 | ★ $118.13 |
| AVG Volume (30 Days) | ★ 3.7M | 814.7K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | ★ 21.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.27 |
| Revenue Next Year | $77.99 | $12.78 |
| P/E Ratio | ★ N/A | $36.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.03 | $71.16 |
| 52 Week High | $86.74 | $355.00 |
| Indicator | IONS | SIMO |
|---|---|---|
| Relative Strength Index (RSI) | 23.68 | 41.21 |
| Support Level | N/A | $234.60 |
| Resistance Level | $77.27 | $273.90 |
| Average True Range (ATR) | 2.83 | 23.50 |
| MACD | -2.87 | -7.96 |
| Stochastic Oscillator | 2.17 | 20.24 |
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid-state storage devices. Its only operating segment is to develop NAND flash controllers and SSD solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company's products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.